

Generic justification


HIQA generically justifies ^{177}Lu PSMA radioligand therapy for the treatment of metastatic castrate-resistant prostate cancer.

Why did we carry out this review?

New practices involving patients' exposure to ionising radiation must be justified by the Health Information and Quality Authority (HIQA).

What is it?

^{177}Lu PSMA radioligand therapy is a cancer medicine that targets certain prostate cancer cells. Once it binds to the cell, it emits a small amount of radioactivity, causing damage to the cell.



Who is it for?

This therapy has been developed for some patients whose prostate cancer has spread to other parts of the body (metastatic disease) and whose disease has progressed despite receiving other types of anti-cancer treatment, such as chemotherapy or hormone therapy.

Our conclusion

The available evidence indicates that ^{177}Lu -PSMA radioligand therapy is a safe and effective treatment, as part of the care of some patients with prostate cancer.

